130 related articles for article (PubMed ID: 9241655)
1. Current status of radioimmunotherapy.
Larson SM; Divgi CR; Scott A; Sgouros G; Graham MC; Kostakoglu L; Scheinberg D; Cheung NK; Schlom J; Finn RD
Nucl Med Biol; 1994 Jul; 21(5):785-92. PubMed ID: 9241655
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
3. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy.
Leichner PK; Koral KF; Jaszczak RJ; Green AJ; Chen GT; Roeske JC
Med Phys; 1993; 20(2 Pt 2):569-77. PubMed ID: 8492765
[TBL] [Abstract][Full Text] [Related]
4. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy dosimetry--a review.
Strand SE; Jönsson BA; Ljungberg M; Tennvall J
Acta Oncol; 1993; 32(7-8):807-17. PubMed ID: 8305230
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
Bischof Delaloye A
Semin Nucl Med; 2000 Jul; 30(3):186-94. PubMed ID: 10928382
[TBL] [Abstract][Full Text] [Related]
8. [Immunoscintigraphy and radioimmunotherapy of cancer using monoclonal antibodies].
Oriuchi N
Gan To Kagaku Ryoho; 1999 May; 26(6):762-7. PubMed ID: 10410144
[TBL] [Abstract][Full Text] [Related]
9. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
11. I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images.
Koral KF; Li J; Dewaraja Y; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3004s-3009s. PubMed ID: 10541335
[TBL] [Abstract][Full Text] [Related]
12. Experimental radioimmunotherapy.
Buchsbaum DJ; Langmuir VK; Wessels BW
Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
[TBL] [Abstract][Full Text] [Related]
13. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma.
Larson SM; Pentlow KS; Volkow ND; Wolf AP; Finn RD; Lambrecht RM; Graham MC; Di Resta G; Bendriem B; Daghighian F
J Nucl Med; 1992 Nov; 33(11):2020-3. PubMed ID: 1432165
[TBL] [Abstract][Full Text] [Related]
14. The role of radioimmunotherapy in bone marrow transplantation.
Corcoran MC; Press OW; Matthews DC; Appelbaum FR; Bernstein ID
Curr Opin Hematol; 1996 Nov; 3(6):438-45. PubMed ID: 9372115
[TBL] [Abstract][Full Text] [Related]
15. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
Kaminski MS; Fig LM; Zasadny KR; Koral KF; DelRosario RB; Francis IR; Hanson CA; Normolle DP; Mudgett E; Liu CP
J Clin Oncol; 1992 Nov; 10(11):1696-711. PubMed ID: 1403053
[TBL] [Abstract][Full Text] [Related]
16. Can occult metastases be treated by radioimmunotherapy?
Dunn RM; Juweid M; Sharkey RM; Behr TM; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2656-9. PubMed ID: 9406721
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy: clinical results and dosimetric considerations.
Langmuir VK
Int J Rad Appl Instrum B; 1992 Feb; 19(2):213-25. PubMed ID: 1534796
[TBL] [Abstract][Full Text] [Related]
18. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled monoclonal antibodies in diagnosis and therapy of cancer. Summary and perspectives.
Britton KE
Acta Oncol; 1996; 35(3):385-90. PubMed ID: 8679271
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
